Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of camrelizumab for third-line recurrent or metastatic colorectal cancer
ChiCTR2100050182Phase 4Not yet recruiting
- Sponsor
- Quanzhou Guangqian Hospital
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in colorectal cancer (CRC), sponsored by Quanzhou Guangqian Hospital. Primary endpoint: Objective response rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100050182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050182.